Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem.
AbstractObjective: To compare side effects between users of two kinds of injectable contraceptives (Depo-medroxy progesterone acetate and Cyclofem).Materials and methods: This cross-sectional descriptive study included 250 women, aged 18-40 years, using Depo-medroxy progesterone acetate (DMPA) or Cyclofem. The volunteers were examined six months after using contraceptive, and they were asked about following symptoms: weight changes, irregular bleeding, dysparounia, vaginal dryness, headache, breast pain, bone pain, and discontinuation reason. The data were analyzed by statistical methods.Results: The important side effects of DMPA were: irregular bleeding (93.60%), weight gain (48%), bone pain (24%) and vaginal dryness (10.40%), while the side effects in the Cyclofem group were: irregular bleeding (65.60%), headache (14.4%) and breast sensitivity (20%). Bleeding pattern changes were the most important problem leading to discontinuation of both contraceptive methods in our participants.Conclusion: The results of the study showed that the most important problem in both groups was change in bleeding pattern. Proper consulting by a trained expert reduces the high amount of discontinuation and their failure rates.
Warwick DP. Culture and the management of family planning programs. Stud Fam Plann 1988; 19:1-18.
D‘Arcangues C, Snow RC. Injectable contraceptives for women. In: Rabe T, Runnebaum B (eds). Fertility Control-Update and Trends. Springer-Verlag, Berlin 1999; 121–49.
Fraser IS, Dennerstein GJ. Depo-Provera use in an Australian metropolitan practice. Med J Aust 1994; 160:553-6.
Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxy progesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687-94.
Haji Kazemi E, Nikpoor S, haghani H. Study of reasons for discontinuation of DMPA in referred womens to IRAN university medical and health centers. RJMS 2003; 9:515-20.
Ruminjo JK, Sckadde-Kigondu CB, Karanja JG, Rivera R, Nasution M, Nutley T. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception 2005; 72:138-45.
Westhoff C, Kems J, Morroni C, Cushman LF, Tiezzi L, Murphy PA. Quick start: novel oral contraceptive initiation method. Contraception 2002;66:141-5.
Guazzelli CA, Jacobucci MS, Barbieri M, Araujo FF, Moron AF. Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects. Contraception 2007; 76:45-8.
Bahamondes L, Diaz J, Petta C, Hall P. Weight variation in users of the once-a- month injectable contraceptive Cyclofem. Adv Contracept 1998; 14:185-92.
Bonny AE, Britto MT, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxy progestrone acetate (DMPA). J Pediatr Adolesc Gynecol 2004; 17:109-15.
Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health 2009; 45: 423-5.
Seymor RJ, Powell LC. Depo-medroxy progestrone acetate as a contraceptive. Obstet Gynecol 1970; 36:589-96.
Piya-Anant M, Koetsawang S, Patrasupapong N, dinchuen P, d´Arcangues C, Piaggio G, et al. Effectiveness of Cyclofem in the treatment of depotmedroxy progestrone acetate induced amenorrhea. Contraception 1998; 57:23-8.
Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxy progesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception 2011; 83:218-22.
Kaunitz AM. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Int J Fertil womens Med1999; 44:110-7.
Kuohung W, Borgatta L, Stubblefield P. Low – dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61:77-82.
Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med 2000; 45:241-7.
Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxy progestrone acetate contraceptive injections. Contraception 2010; 81: 281-91.
Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogestrone acetate injectable contraceptive use. Contraception 2008; 77: 67-76.
Shaarawy M, EL-Mallah SY, Seoudi S, Hassan M, Mohsen Ia. Effects of the long-term use of depot medroxy progestrone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 2006; 74: 297-302.
Bahamondes L, Juliato CT, Villarreal M, Sobreira- Lima B, Simoes JA, Dos Santos Fernandes AM. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception 2006; 74:259-63.
Gupta N, O´Brien R, Jacobsen LJ, Davis A, Zuckerman A, Supran S, et al. Mood changes in adolescents using depot-medroxy progestrone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14:71-6.
Westhoff C. Depot medroxy progestrone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996; 41:401-6.
Westhoff C, Wieland D, Tiezzi I. Depression in users of depo-medroxy progestrone acetate. Contraception 1995; 51:351-4.
Hubacher D, Lopez L, steiner MJ, Dorflinger L.Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113-8.
Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxy progestrone acetate subcutaneous injection 104 mg. Contraception 2006;74:234-8.
Hall PE. New once-a-month injectable contraceptives, with particular reference to Cyclofem/ Cyclo-Provera. Int J Gynecol Obstet 1998;62:S43-56.
Bahamondes L, maradiegue E, Diaz J, Trelles J, Escanhoela C, Petta C, et al. Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem. Adv Contracept 1999; 15:1-7.
Simbar M, Tehrani FR, Hashemi Z, Zham H, Fraser IS. A comparative study of Cyclofem and depot medroxyprogestrone acetate (DMPA) effects on endometrial vasculature. J Fam Plann Reprod Health Care 2007; 33:271-6.
Garza-Flores J, Moraks del Olmo A, Fuziwara JL, Figueroa JG, Alonso A, Monroy J, Et al. Introduction of cyclofem once-a-month injectable contraceptive in Mexico. Contraception 1998; 58:7-12.
31-Sang GW, Shao QX, Ge RS, Ge JL, Chen JK, Song S, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. Contraception 1995; 51:167-83.